Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 39, 2009 - Issue 9
Submit an article Journal homepage
212
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species

E. F. ChooDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USACorrespondence[email protected]
,
J. P. DriscollDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
,
J. FengDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
,
B. LiedererDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
,
E. PliseDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
,
N. RandolphArray Biopharma, Drug Metabolism Department, Boulder, CO, USA
,
Y. ShinDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
,
S. WongDrug Metabolism and Pharmacokinetics Department, Genentech, Inc., South San Francisco, CA, USA
&
Y. RanPharmaceutics Department, Genentech, Inc., South San Francisco, CA, USA
 show all
Pages 700-709 | Received 04 Feb 2009, Accepted 23 Apr 2009, Published online: 20 May 2009

References

  • Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharmaceut 10:201–27.
  • Boyer SJ. (2006). Raf modulators and methods of use. Expert Opin Ther Patent 16:1031–6.
  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417:949–54.
  • Gollob JA, Wilhelm S, Carter C, Kelley SL. (2006). Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Sem Oncol 33:392–406.
  • Hansen JD, Grina J, Newhouse B, Welch M, Topalov G, Littman N, Callejo M, Gloor S, Martinson M, Laird E, et al. (2008). Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett 18:4692–5.
  • Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, et al. (2006). Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66:999–1006.
  • Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O’brien C, Modrusan Z, Seshagiri S, Lackner M, et al. (2009). Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 69:3042–51.
  • Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. (2007). Selective Raf inhibition in cancer therapy. Expert Opin Ther Target 11:1587–609.
  • Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P. (1997). Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharmaceut Sci 86:584–90.
  • Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. (1986). Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharmaceut Sci 75:271–4.
  • Madhunapantula SV, Robertson GP. (2008). Is B-Raf a good therapeutic target for melanoma and other malignancies? Cancer Res 68:5–8.
  • Mahmood I, Balian JD. (1996). Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887–95.
  • Mercer KE, Pritchard CA. (2003). Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25–40.
  • Panka DJ, Atkins MB, Mier JW. (2006). Targeting the mitogen- activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res 12:2371s–5s.
  • Rowland M, Tozer TN. (1995). Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins.
  • Schreck R, Rapp UR. (2006). Raf kinases: Oncogenesis and drug discovery. Int J Cancer 15;119(10):2261–71.
  • Sebolt-Leopold JS, Herrera R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937–47.
  • Tibbitts J. (2003). Issues related to the use of canines in toxicologic pathology — issues with pharmacokinetics and metabolism. Toxicol Pathol 31(Suppl.):17–24.
  • Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–109.
  • Wilhelm S, Chien DS. (2002). BAY 43-9006: preclinical data. Curr Pharmaceut Design 8:2255–7.
  • Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, Choo EF. (2009). Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)- 2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther 329:360–7.
  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, et al. (2002). Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62:6451–5.
  • Zebisch A, Troppmair J. (2006). Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 63:1314–30.
  • Zhou R, Moench P, Heran C, Lu X, Mathias N, Faria TN, Wall DA, Hussain MA, Smith RL, Sun D. (2005). pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. Pharmaceut Res 22:188–92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.